Optimal time of dual antiplatelet therapy in patients with coronary heart disease (literature review)

Author:

Gorgulko A. P.1ORCID,Baranov A. A.1ORCID,Khelimskii D. A.1ORCID,Krestyaninov O. V.1ORCID,Badoyan A. G.1ORCID

Affiliation:

1. E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation

Abstract

However, the choice of optimal time of DAPT after PCI is still a difficult and urgent problem for the attending physician. An increase in DAPT duration after PCI correlates with a lower frequency of ischemic events. At the same time, with a longer DAPT regime, there is a more significant increase in the risks of postoperative bleeding. Hence, it is important to find a balance between the potential risks of bleeding and the expected benefits in reducing ischemic events, while taking into account the individual clinical characteristics of each patient. Intravascular imaging methods, such as intravascular coherence tomography, allow obtaining a highly informative lifetime morphological assessment of the coronary arteries, the formation of the neointima and the malposition of the implanted stent, which, in turn, can help in choosing the optimal timing of the DAPT and prevention of undesirable side events.

Publisher

Cardiology Research Institute

Subject

Cardiology and Cardiovascular Medicine,Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,Medicine (miscellaneous),Internal Medicine

Reference41 articles.

1. Bittl J.A., Baber U., Bradley S.M., Wijeysundera D.N. Duration of dual antiplatelet therapy: a systematicreview for the 2016 ACC/AHA guideline focusedupdate on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2016;68(10):1116–1139. DOI: 10.1016/j.jacc.2016.03.512.

2. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur. Heart J. 2013;34(39):3028–3034. DOI: 10.1093/eurheartj/eht356.

3. Frigoli E., Smits P., Vranckx P., Ozaki Y., Tijssen J., Jüni P. et. al. Design and rationale of the management of high bleeding risk patients post bioresorbable polymer coated stent implantation with an abbreviated versus standard DAPT regimen (MASTER DAPT) study. Am. Heart J. 2019;209:97–105. DOI: 10.1016/j.ahj.2018.10.009.

4. Urban P., Mehran R., Colleran R., Angiolillo D.J., Byrne R.A., Capodanno D. et. al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur. Heart J. 2019;40(31):2632–2653. DOI: 10.1093/eurheartj/ehz372.

5. Stone G.W., Rizvi A., Newman W., Mastali K., Wang J.C., Caputo R. et. al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med. 2010;362(18):1663–1674. DOI: 10.1056/NEJMoa0910496.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3